source
- Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial resultsBraveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
- European regulators approve Fractyl Health's first GLP-1 gene therapy clinical trialEuropean regulators have given the green light for Fractyl Health, a biotech near Boston, to begin its first human study of a GLP-1 gene therapy. The therapy aims to provide a one-time treatment t…